Connection

Alicia Jenkins to Aged

Back to Details
This is a "connection" page, showing publications Alicia Jenkins has written about Aged.
Alicia Jenkins
Connection Strength
0.630
Aged
  1. Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes. Sci Rep. 2021 09 21; 11(1):18708.
    View in: PubMed
    Score: 0.064
  2. Insulin micro-secretion in Type 1 diabetes and related microRNA profiles. Sci Rep. 2021 06 03; 11(1):11727.
    View in: PubMed
    Score: 0.063
  3. Long-Term Glycemic Variability and Vascular Complications in Type 2 Diabetes: Post Hoc Analysis of the FIELD Study. J Clin Endocrinol Metab. 2020 10 01; 105(10).
    View in: PubMed
    Score: 0.060
  4. Clinical correlates of serum pigment epithelium-derived factor in type 2 diabetes patients. J Diabetes Complications. 2014 May-Jun; 28(3):353-9.
    View in: PubMed
    Score: 0.038
  5. An algorithm guiding patient responses to real-time-continuous glucose monitoring improves quality of life. Diabetes Technol Ther. 2011 Feb; 13(2):105-9.
    View in: PubMed
    Score: 0.031
  6. Associations among smoking status, lifestyle and lipoprotein subclasses. J Clin Lipidol. 2010 Nov-Dec; 4(6):522-30.
    View in: PubMed
    Score: 0.030
  7. Increased coated-platelet levels in chronic haemodialysis patients. Nephrology (Carlton). 2009 Apr; 14(2):148-54.
    View in: PubMed
    Score: 0.027
  8. An Assessment of Clinical Continuous Glucose Monitoring Targets for Older and High-Risk People Living with Type 1 Diabetes. Diabetes Technol Ther. 2023 02; 25(2):108-115.
    View in: PubMed
    Score: 0.017
  9. Relative leucocyte telomere length is associated with incident end-stage kidney disease and rapid decline of kidney function in type 2 diabetes: analysis from the Hong Kong Diabetes Register. Diabetologia. 2022 02; 65(2):375-386.
    View in: PubMed
    Score: 0.016
  10. The relationship of neutrophil elastase and proteinase 3 with risk factors, and chronic complications in type 2 diabetes: A Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) sub-study. Diab Vasc Dis Res. 2021 Jul-Aug; 18(4):14791641211032547.
    View in: PubMed
    Score: 0.016
  11. FKBPL is associated with metabolic parameters and is a novel determinant of cardiovascular disease. Sci Rep. 2020 12 10; 10(1):21655.
    View in: PubMed
    Score: 0.015
  12. Six Months of Hybrid Closed-Loop Versus Manual Insulin Delivery With Fingerprick Blood Glucose Monitoring in Adults With Type 1 Diabetes: A Randomized, Controlled Trial. Diabetes Care. 2020 12; 43(12):3024-3033.
    View in: PubMed
    Score: 0.015
  13. Shortened Relative Leukocyte Telomere Length Is Associated With Prevalent and Incident Cardiovascular Complications in Type 2 Diabetes: Analysis From the Hong Kong Diabetes Register. Diabetes Care. 2020 09; 43(9):2257-2265.
    View in: PubMed
    Score: 0.015
  14. Higher Serum Sex Hormone-Binding Globulin Levels Are Associated With Incident Cardiovascular Disease in Men. J Clin Endocrinol Metab. 2019 12 01; 104(12):6301-6315.
    View in: PubMed
    Score: 0.014
  15. High plasma FGF21 levels predicts major cardiovascular events in patients treated with atorvastatin (from the Treating to New Targets [TNT] Study). Metabolism. 2019 04; 93:93-99.
    View in: PubMed
    Score: 0.013
  16. Cross-sectional and longitudinal determinants of serum sex hormone binding globulin (SHBG) in a cohort of community-dwelling men. PLoS One. 2018; 13(7):e0200078.
    View in: PubMed
    Score: 0.013
  17. Effect of a high-egg diet on cardiometabolic risk factors in people with type 2 diabetes: the Diabetes and Egg (DIABEGG) Study-randomized weight-loss and follow-up phase. Am J Clin Nutr. 2018 06 01; 107(6):921-931.
    View in: PubMed
    Score: 0.013
  18. The association between total phthalate concentration and non-communicable diseases and chronic inflammation in South Australian urban dwelling men. Environ Res. 2017 10; 158:366-372.
    View in: PubMed
    Score: 0.012
  19. Baseline Circulating FGF21 Concentrations and Increase after Fenofibrate Treatment Predict More Rapid Glycemic Progression in Type 2 Diabetes: Results from the FIELD Study. Clin Chem. 2017 Jul; 63(7):1261-1270.
    View in: PubMed
    Score: 0.012
  20. Liberal Glycemic Control in Critically Ill Patients With Type 2 Diabetes: An Exploratory Study. Crit Care Med. 2016 09; 44(9):1695-703.
    View in: PubMed
    Score: 0.011
  21. Muscle grip strength predicts incident type 2 diabetes: Population-based cohort study. Metabolism. 2016 06; 65(6):883-92.
    View in: PubMed
    Score: 0.011
  22. Opposite associations between alanine aminotransferase and ?-glutamyl transferase levels and all-cause mortality in type 2 diabetes: Analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Metabolism. 2016 May; 65(5):783-793.
    View in: PubMed
    Score: 0.011
  23. Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study. Diabetologia. 2015 Sep; 58(9):2035-44.
    View in: PubMed
    Score: 0.010
  24. Serum 25-hydroxyvitamin D: a predictor of macrovascular and microvascular complications in patients with type 2 diabetes. Diabetes Care. 2015 Mar; 38(3):521-8.
    View in: PubMed
    Score: 0.010
  25. The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study. Diabetologia. 2015 Mar; 58(3):464-73.
    View in: PubMed
    Score: 0.010
  26. Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia. 2014 Nov; 57(11):2296-303.
    View in: PubMed
    Score: 0.010
  27. HDL-C and HDL-C/ApoA-I predict long-term progression of glycemia in established type 2 diabetes. Diabetes Care. 2014 Aug; 37(8):2351-8.
    View in: PubMed
    Score: 0.010
  28. Apolipoprotein-defined and NMR lipoprotein subclasses in the veterans affairs diabetes trial. J Diabetes Complications. 2013 Nov-Dec; 27(6):627-32.
    View in: PubMed
    Score: 0.009
  29. The metabolic syndrome and CVD outcomes for a central Australian cohort. Diabetes Res Clin Pract. 2013 Jun; 100(3):e70-3.
    View in: PubMed
    Score: 0.009
  30. Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2012 Dec; 97(12):4701-8.
    View in: PubMed
    Score: 0.009
  31. Serum apolipoproteins are associated with systemic and retinal microvascular function in people with diabetes. Diabetes. 2012 Jul; 61(7):1785-92.
    View in: PubMed
    Score: 0.008
  32. Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study. Diabetes Care. 2012 Feb; 35(2):218-25.
    View in: PubMed
    Score: 0.008
  33. Lipid treatment guidelines and cardiovascular risk for Aboriginal people in Central Australia. Med J Aust. 2009 May 18; 190(10):552-6.
    View in: PubMed
    Score: 0.007
  34. Associations of inflammatory and hemostatic variables with the risk of recurrent stroke. Stroke. 2005 Oct; 36(10):2143-7.
    View in: PubMed
    Score: 0.005
  35. Prediction of myocardial infarction by N-terminal-pro-B-type natriuretic peptide, C-reactive protein, and renin in subjects with cerebrovascular disease. Circulation. 2005 Jul 05; 112(1):110-6.
    View in: PubMed
    Score: 0.005
  36. Prediction of heart failure by amino terminal-pro-B-type natriuretic peptide and C-reactive protein in subjects with cerebrovascular disease. Hypertension. 2005 Jan; 45(1):69-74.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.